It was suggested that this dual action of metformin (insulin reduction and mTOR inhibition) makes it a particularly attractive target for evaluation in breast cancer [50,51,101,102,161,164] as well as some other, e.g. colon cancer. This evidence concerns the gene INS and breast cancer.